Cellectar Biosciences CLRB 深 沪
等待开盘 12-19 09:30:00 美东时间
2.71
-0.030
-1.09%
华盛通- 最 高2.9799
- 今 开2.76
- 成交量 2.47万股
- 最 低 2.71
- 昨 收 2.74
- 总市值 865.03万
- 52周最高 20.595
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.45
- 委 比 64.07%
- 总股本 319.20万
- 历史最高 276000.00
- 量 比 0.24
- 振 幅 9.85%
- 历史最低 2.71
- 每 手 1
- 风险率 2.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Cellectar Biosciences has signed a multi-year supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of Ac-225 and At-211, critical alpha-emitting radioisotopes. This collaboration supports Cellectar's drug development programs, particularly the targeted alpha therapy candidate CLR-225 for treating solid tumors like pancreatic cancer. Ionetix is expanding its cyclotron production to meet the growing demand for ...
12-16 13:05
Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.53) by 44.2 percent. This is a 88.25 percent increase over losses of $(12.00) per share
11-13 20:03
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cellectar Biosciences announced financial results for Q3 2025 and updates on its pipeline, including plans to submit a Conditional Marketing Authorization application for iopofosine I 131 in Europe for refractory Waldenstrom's macroglobulinemia in 2026. The company also initiated a Phase 1b study for CLR 125 in triple-negative breast cancer (TNBC) and received rare pediatric drug designation for iopofosine I 131 in inoperable relapsed/refractory ...
11-13 12:20
Earnings Outlook For Cellectar Biosciences
Cellectar Biosciences (NASDAQ:CLRB) is set to give its latest quarterly earning...
11-13 01:03
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Cellectar Biosciences, Inc. will report its third-quarter 2025 financial results and provide a corporate update on November 13, 2025, at 8:30 a.m. ET. A conference call and webcast will be held, accessible via 1-800-717-1738 (Conference ID: 42734) or the provided webcast link. A replay will be available on the company’s Investor Relations website. Cellectar focuses on developing radiopharmaceuticals for cancer treatment using its Phospholipid Dru...
11-06 13:05
CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
CLRB stock has given up its prior gain. Cellectar Biosciences shares were tradi...
10-27 21:27
Cellectar Biosciences shares are trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
Cellectar Biosciences shares are trading higher after the company received Rare...
10-27 20:33
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
Cellectar Biosciences announced that the FDA granted Rare Pediatric Drug Designation to iopofosine I 131 for treating inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG). Interim data from the CLOVER-2 Phase 1b trial showed extended progression-free survival (PFS) and overall survival (OS), with patients experiencing disease control and reduced tumor volume. The drug demonstrated a favorable safety profile, with no severe off...
10-27 12:30
Cellectar Biosciences Presented Preclinical Data On CLR 121225, A Novel Actinium-Based Alpha-Emitter For Pancreatic Ductal Adenocarcinoma Which Has Completed IND-Enabling Studies And May Advance To A Phase 1 Trial
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief
10-14 20:37
